Expertise in
12
conditions

Dr. Mark W. Kieran

Hematology | Oncology
Dana-Farber Cancer Institute
450 Brookline Ave, 
Boston, MA 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
12
conditions
Dana-Farber Cancer Institute
450 Brookline Ave, 
Boston, MA 

Overview

Mark Kieran is a Hematologist and an Oncologist practicing medicine in Boston, Massachusetts.

Dr. Kieran is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Brain Tumor, Glioma, Gliomatosis Cerebri, and Posterior Fossa Tumor.

He is actively involved in clinical research, co-authoring 175 peer reviewed articles and participating in 8 clinical trials.

Specialties

Hematology
Oncology

Licenses

Pediatric Hematology-Oncology in MA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Cigna
  • EPO
  • HMO
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 2 Less Insurance Carriers -

Locations

Dana-Farber Cancer Institute
450 Brookline Ave, Boston, MA 02215

Additional Areas of Focus

Dr. Kieran has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase II Study of Metronomic and Targeted Anti-angiogenesis Therapy for Children With Recurrent/Progressive Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors
A Phase II Study of Metronomic and Targeted Anti-angiogenesis Therapy for Children With Recurrent/Progressive Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors
Enrollment Status: Recruiting
Publish Date: February 23, 2026
Intervention Type: Drug
Study Drugs: Bevacizumab, Thalidomide, Celecoxib, Fenofibric Acid, Etoposide, Cyclophosphamide, Etoposide Phosphate, Cytarabine
Study Phase: Phase 2
A Phase II Study of Binimetinib in Children and Adults With NF1 Associated Plexiform Neurofibromas (PNOC010)
A Phase II Study of Binimetinib in Children and Adults With NF1 Associated Plexiform Neurofibromas (PNOC010)
Enrollment Status: Completed
Publish Date: May 02, 2025
Intervention Type: Drug
Study Drug: Binimetinib
Study Phase: Phase 2
Phase II Open-label Global Study to Evaluate the Effect of Dabrafenib in Combination With Trametinib in Children and Adolescent Patients With BRAF V600 Mutation Positive Low Grade Glioma (LGG) or Relapsed or Refractory High Grade Glioma (HGG)
Phase II Open-label Global Study to Evaluate the Effect of Dabrafenib in Combination With Trametinib in Children and Adolescent Patients With BRAF V600 Mutation Positive Low Grade Glioma (LGG) or Relapsed or Refractory High Grade Glioma (HGG)
Enrollment Status: Completed
Publish Date: December 13, 2023
Intervention Type: Drug
Study Drugs: Dabrafenib, Trametinib, Carboplatin with Vincristine
Study Phase: Phase 2
A Phase II Study of Cabozantinib (XL184) for Plexiform Neurofibromas in Subjects With Neurofibromatosis Type 1 in Children and Adults
A Phase II Study of Cabozantinib (XL184) for Plexiform Neurofibromas in Subjects With Neurofibromatosis Type 1 in Children and Adults
Enrollment Status: Completed
Publish Date: May 24, 2023
Intervention Type: Drug
Study Drug: Cabozantinib
Study Phase: Phase 2
A Study of INFUSE Bone Graft (Recombinant Human Bone Morphogenetic Protein-2/Absorbable Collagen Sponge) in the Treatment of Tibial Pseudarthrosis in Neurofibromatosis 1 (NF1)
A Study of INFUSE Bone Graft (Recombinant Human Bone Morphogenetic Protein-2/Absorbable Collagen Sponge) in the Treatment of Tibial Pseudarthrosis in Neurofibromatosis 1 (NF1)
Enrollment Status: Terminated
Publish Date: October 27, 2021
Intervention Type: Procedure, Device
Study Phase: Not Applicable
A Pilot, Non-Therapeutic NeuroImaging Study of 18F-FLT in Pediatric Patients With Newly Diagnosed Central Nervous System Tumors
A Pilot, Non-Therapeutic NeuroImaging Study of 18F-FLT in Pediatric Patients With Newly Diagnosed Central Nervous System Tumors
Enrollment Status: Terminated
Publish Date: October 20, 2021
Intervention Type: Radiation, Drug
Study Phase: Phase 1
Open-label, Phase 2 Study of Bevacizumab in Children and Young Adults With Neurofibromatosis 2 and Progressive Vestibular Schwannomas That Are Poor Candidates for Standard Treatment With Surgery or Radiation
Open-label, Phase 2 Study of Bevacizumab in Children and Young Adults With Neurofibromatosis 2 and Progressive Vestibular Schwannomas That Are Poor Candidates for Standard Treatment With Surgery or Radiation
Enrollment Status: Completed
Publish Date: February 12, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase II Study of Everolimus (RAD001) for Children With Chemotherapy and/or Radiation-Refractory Progressive or Recurrent Low-Grade Gliomas
A Phase II Study of Everolimus (RAD001) for Children With Chemotherapy and/or Radiation-Refractory Progressive or Recurrent Low-Grade Gliomas
Enrollment Status: Completed
Publish Date: August 15, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 7 Less Clinical Trials

175 Total Publications

Reaching for the cure as progeria research comes of age at the 12th international scientific workshop.
Reaching for the cure as progeria research comes of age at the 12th international scientific workshop.
Journal: Nature aging
Published: June 18, 2026
Similar Doctors
Expertise in
18
conditions
Dr. Steven G. Dubois
Hematology | Oncology
Expertise in
18
conditions
Dr. Steven G. Dubois
Hematology | Oncology
Referral may be required

Dana-Farber Cancer Institute

450 Brookline Ave, 
Boston, MA 
 (0.1 miles away)
877-442-3324
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Steven Dubois is a Hematologist and an Oncologist practicing medicine in Boston, Massachusetts. Dr. Dubois is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Ewing Sarcoma, Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, and Osteosarcoma. Dr. Dubois is currently accepting new patients.

Expertise in
24
conditions
Dr. Matthew M. Heeney
Hematology | Oncology
Expertise in
24
conditions
Dr. Matthew M. Heeney
Hematology | Oncology
Referral may be required

Dana-Farber Cancer Institute

450 Brookline Ave, 
Boston, MA 
 (0.1 miles away)
877-442-3324
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Matthew Heeney is a Hematologist and an Oncologist practicing medicine in Boston, Massachusetts. Dr. Heeney is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Sickle Cell Disease, Congenital Hemolytic Anemia, Hemolytic Anemia, Hemoglobinopathy, and Splenectomy. Dr. Heeney is currently accepting new patients.

Expertise in
23
conditions
Dr. Katherine A. Janeway
Hematology | Oncology
Expertise in
23
conditions
Dr. Katherine A. Janeway
Hematology | Oncology
Referral may be required

Dana-Farber Cancer Institute

450 Brookline Ave, 
Boston, MA 
 (0.1 miles away)
877-442-3324
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Katherine Janeway is a Hematologist and an Oncologist practicing medicine in Boston, Massachusetts. Dr. Janeway is highly rated in 23 conditions, according to our data. Her clinical expertise encompasses Osteosarcoma, Adult Soft Tissue Sarcoma, Ewing Sarcoma, Neuroepithelioma, and Bone Marrow Aspiration. Dr. Janeway is currently accepting new patients.

Frequently Asked Questions about Dr. Mark W. Kieran

How do I make an appointment with Dr. Mark W. Kieran?

You can book an appointment with Dr. Mark W. Kieran by calling their office at 617-632-3000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Mark W. Kieran a top-rated expert for Brain Tumor?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Mark W. Kieran is classified as an Distinguished expert for Brain Tumor, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Mark W. Kieran specialize in?

While Dr. Mark W. Kieran is a Hematology, they have specific expertise in Brain Tumor, Glioma, and Gliomatosis Cerebri. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Mark W. Kieran participate in research or clinical trials?

Yes. Dr. Mark W. Kieran has published 175 articles and abstracts on conditions like Brain Tumor. You can view a list of Dr. Mark W. Kieran's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Mark W. Kieran accept my insurance?

Dr. Mark W. Kieran accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 617-632-3000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kieran's expertise for a condition
ConditionClose
    View All 14 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile